Exercise after prostate cancer diagnosis

Exercise and Cancer Survivorship: Impact on Health Outcomes and Quality of Life

Volumn , Issue , 2010, Pages 113-139

  Mina, Daniel Santa ^a   Ritvo, Paul ^b   Segal, Roanne ^c   Culos Reed, N ^d   Alibhai, Shabbir M H ^e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b CANCER CARE ONTARIO   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79951906307     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-1173-5_7     Document Type: Chapter

References (83)

1. American Cancer Society, Cancer Facts & Figures 2008, 1-72, 2008.
2. Canadian Cancer Society/National Cancer Institute of Canada. (2008) Canadian Cancer Statistics, pp. 1-72.
3. Quinn M, Babb P. (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. Br J Urol Int 90:162-173.
4. Hsing A, Tsao WL, Devesa SS. (1999) International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85:60-67.
5. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer V. I. 2008, 1-44, 2008.
6. Fowler FJ, Barry MJ, Lu-Yao G, Wasson J, Roman A, Wennberg J. (1995) Effect of radical prostatectomy for prostate cancer on patient quality of life: Results from a medicare survey. Urology 45:1007-1115.
7. Moore KN, Estey A. (1999) The early post-operative concerns of men after radical prostatectomy. J Adv Nurs 29:1121-1129.
8. Haythornthwaite JA, Raja SN, Fisher B, Frank SM, Brendler CB, Shir Y. (1998) Pain and quality of life following radical retropubic prostatectomy. J Urol 160:1761-1764.
9. Meuleman E. (2003) Erectile function after radical prostatectomy: a review. Eur Urol 43:95-102.
10. Peschel RE, Colberg JW. (2003) Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 4:233-241.
11. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH. (1995) Quality-oflife outcomes in men treated for localized prostate cancer. JAMA 273:129-135.
12. Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G. (1996) Waning sexual function - the most important disease-specific distress for patients with prostate cancer. Br J Cancer 73:1417-1421.
13. Klotz L, Kiberl AS, Sanda M, Thompson I, Clarke N (2008) Surveillance Therapy Against Radical Treatment Trial (START), September 5, 2008.
14. Kennedy TJ, Sonneland AM, Marlett MM, Troup RH. (1992) Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer. J Urol 147:891-893.
15. Macfarlane MT, Abi-Aad A, Stein A, Danella J, Belldegrum A, De Kernion JB. (1993) Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J Urol 150:132-134.
16. Oesterling JE, Andrews PE, Suman VJ, Zincke H, Myers RP. (1993) Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 149:779-782.
17. Strum SE, McDermed JE, Scholz MC, Johnson H, Tisman G. (1997) Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79:933-941.
18. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. (2000) Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163:181-186.
19. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599-603.
20. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656-3661.
21. Alibhai SMH, Gogov S, Allibhai Z. (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60:201-215.
22. Chander S, Choo R, Danjoux C, Morton G, Pearse A, Deboer G, Szumacher E, Loblaw A, Cheung P, Woo T. (2005) Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. Int J Radiat Oncol Biol Phys 62:719-724.
23. Stoch SA, Parker RA, Chen L, Bubley G, Ko Y, Vincellette A, Greenspan SL. (2001) Bone loss in men with prostate cancer treated with gonadotropin- releasing hormone agonists. J Clin Endocrinol Metab 86:2787-2791.
24. Preston DM, Torrens JI, Harding P, Howard RS, Duncan WE, Mcleod DG. (2002) Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prost Cancer Prost Dis 5:304-310.
25. Pickett M, Bruner DW, Joseph A, Burgraf V. (2000) Prostate cancer elder alert: living with treatment choices and outcomes. J Gerontol Nurs 26:22-34.
26. Cassileth BR, Soloway MS, Vogelzang NJ, Chou JM, Schellhammer PD, Seidmon EJ, Kennealey GT. (1992) Quality of life and psychosocial status in stage D prostate cancer. Qual Life Res 1:323-330.
27. Cleary PD, Morrissey G, Oster G. (1995) Health-related quality of life in patients with advanced prostate cancer. Qual Life Res 4:207-220.
28. Alibhai SMH, Rahman S, Warde PR, Jewett MA, Jaffer T, Cheung AM. (2006) Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists. Urology 68:126-131.
29. Basaria S, Lieb JI, Tanǧ AM, De Weese T, Carducci M, Eisenberger M, Dobs AS. (2002) Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrin 56:779-786.
30. Soyupek F, Soyupek H, Ozorak A. (2008) Androgen deprivation therapy for prostate cancer: effects on hand function. Urol Oncol 26:141-146.
31. Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U. (2006) Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. Br J Urol Int 98:20-27.
32. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512.
33. Berthold DR, Pond GR, Roessner M, De Wit R, Eisenberger M, Tannock IF. (2008) Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14:2763-2767.
34. Picus J, Schultz M. (1999) Docetaxel (taxotere) as monotherapy in the treatment of hormonerefractory prostate cancer: preliminary Results. Semin Oncol 26:14-18.
35. Casperson CJ, Powell KE, Christenson GM. (1985) Physical activity, exercise, and physical fitness: definition and distinctions for health-related research. Public Health Rep 100:126-131.
36. Bouchard C, Shephard RJ, Physical Activity, Fitness, and Health: International Proceedings and Consensus Statement. Physical activity, fitness, and health: the model and key concepts, Windsor, ON: Human Kinetics, 1994, 77-88.
37. Paffenbarger RS, Hyde RT, Wing AL, Hsieh CC. (1986) Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med 314:605-613.
38. Warburton DER, Nicol CW, Bredin SSD. (2006) Health benefits of PA: the evidence. Can Med Assoc J 174:801-809.
39. Kampert JB, Blair SN, Barlow CE, Kohl HW III, Harold W. (1996) Physical activity, physical fitness, and all-cause and cancer mortality: a prospective study of men and women. Ann Epidemiol 6:452-457.
40. Friedenreich CM, Thune I. (2001) A review of PA and prostate cancer risk. Cancer Causes Control 12:461-475.
41. Min LI. (2003) Physical activity and cancer prevention-data from epidemiologic studies. Med Sci Sports Exerc 35:1823-1827.
42. Giovannucci EL, Liu Y, Leitzmann MF, Stampfer MJ, Willett WC. (2005) A prospective study of PA and incident and fatal prostate cancer. Arch Intern Med 165:1005-1010.
43. Tymchuk CN, Barnard RJ, Heber D, Aronson WJ. (2001) Evidence of an inhibitory effect of diet and exercise on prostate cancer cell growth. J Urol 166:1185-1189.
44. Ngo TH, Barnard RJ, Tymchuk CN, Cohen P, Aronson WJ. (2002) Effect of diet and exercise on serum insulin, IFG-I, and IFGBP-1 levels and growth of LNCaP cells in vitro. Cancer Causes Control 13:929-935.
45. Galvão DA, Taaffe DR, Spry N, Newton RU. (2007) Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prost Cancer Prost Dis 8:1-7.
46. Ngo TH, Barnard RJ, Leung P, Cohen P, Aronson WJ. (2003) Insulin-like growth factor (IGFI) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 144:2319-2324.
47. Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA. (2003) A low-fat diet and/or strenuous exercise alters the IFG axis in vivo and reduces prostate tumor cell growth in vitro. Prostate 56:201-206.
48. Leung PS, Aronson WJ, Ngo TH, Golding LA, Barnard RJ. (2004) Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro. J Appl Physiol 96:450-454.
49. Tymchuk CN, Tessier SB, Aronson WJ, Barnard RJ. (1998) Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer 31:127-131.
50. Barnard RJ, Leung PS, Aronson WJ, Cohen P, Golding LA. (2007) A mechanism to explain how regular exercise might reduce the risk for clinical prostate cancer. Eur J Cancer Prev 16:415-421.
51. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, Wells GA. (May 1. 2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21:1653-1659.
52. Segal RJ, Reid R, Proulx C, Courneya K, Sigal R, Kenny G, Prud'homme S, Wells MG, (2009) Randomized controlled trial of resistance or aerobic exercise in men receiving radiation for prostate cancer. Journal of Clinical Oncology. 27:344-351.
53. Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Kanemitsu Y, Newton RU. (2006) Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38:2045-2052.
54. Duke University Medical Center. (2008) Exercise May Lead to Faster Prostate Tumor Growth, April 14, 2008.
55. Thorsen L, Courneya KS, Stevinson C, Fossa SD. (2008) A systematic review of PA in prostate cancer survivors: outcomes, prevalence, and determinants. Supportive Care Cancer 16:987-997.
56. Durak EP, Harris J, Ceriale SM. (2001) The effects of exercise on quality of life improvement in cancer survivors: the Results of a national survey. J Exerc Online 4:21-28.
57. Stevinson C, Lawlor D, Fox K. (2004) Exercise interventions for cancer patients: systematic review of controlled trials. Cancer Causes Control 15:1035-1056.
58. Freedland SJ, Krupski TL, Moul JW. (2006) Update on outcomes research databases in prostate cancer 2006. Curr Opin Urol 16:168-172.
59. Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Elashoff D, Terris MK. (2004) Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the shared equal access regional cancer hospital database study group. J Clin Oncol 22:446-453.
60. Chang SS, Duong DT, Wells N, Cole EE, Smith JA, Cookson MS. (2004) Predicting blood loss and transfusion requirements during radical prostatectomy: the significant negative impact of increasing body mass index. J Urol 171:1861-1865.
61. Windsor PM, Nicol KF, Potter J. (2004) A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer 101:550-557.
62. Monga U, Garber SL, Thornby J, Vallbona C, Kerrigan A, Monga TN, Zimmerman KP. (2007) Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch Phys Med Rehabil 88:1416-1422.
63. Smith JA, Jr. Soloway MS, Young MJ. (1999) Complications of advanced prostate cancer. Urology 54:8-14.
64. Williams MB, Hernandez J, Thompson I. (2005) Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J Urol 173:1067-1071.
65. Clay CA, Perera S, Wagner JM, Miller ME, Nelson JB, Greenspan SL. (2007) Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther 87:1325-1333.
66. Breunis H, Leach M, Naglie G, Tannock IF, Fleshner NE, Krahn M, Duff-Canning S, Tomlinson G, Warde P, Alibhai SM. (2008) Androgen deprivation therapy (ADT) and physical function in men with nonmetastatic prostate cancer. J Clin Oncol 27:4895.
67. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, Gilliland FD, Stanford JL. (2002) Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Nat Cancer Inst 94:430-437.
68. Daniell HW. (1997) Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439-444.
69. Lee H, McGovern K, Finkelstein JS, Smith MR. (2005) Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 104:1633-1637.
70. Shahinian VB, Yong-Fang K, Freeman JL, Goodwin JS. (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164.
71. Oeffelein MG, Ricchuiti V, Conrad W, Resnick M. (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005-1007.
72. Carmack Taylor CL, Demoor C, Smith MA, Dunn AL, Basen-Engquist K, Nielsen I, Pettaway C, Sellin R, Massey P, Gritz ER. (2006) Active for life after cancer: A randomized trial examining a lifestyle PA program for prostate cancer patients. Psycho-Oncology 15:847-862.
73. Prochaska JO, Velicer WF. (1997) The transtheoretical model of health behavior change. Am J Health Prom 12:38-48.
74. Prochaska JO, Di Clemente CC. (1983) Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 51:390-395.
75. Bandura A. (1986) Social foundations of thought and action: a social cognitive theory. Prentice Hall, Englewood Cliffs, NJ.
76. Bandura A. (1997) Self-efficacy: the exercise of control. W. H. Freeman and Company, New York.
77. Culos-Reed SN, Robinson JL, Lau H, O'Connor K, Keats MR. (2007) Benefits of a PA intervention for men with prostate cancer. J Sport Exerc Psych 29:118-127.
78. Courneya KS, Friedenreich CM. (Fall 1997) Relationship between exercise pattern across the cancer experience and current quality of life in colorectal cancer survivors. J Altern Complement Med 3:215-226.
79. Culos-Reed SN, Robinson JW, Lau H, Stephenson L, Keats M, Norris S, Kline G. (2007) Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention Support Canre Cancer. 17 (online).
80. Berglund G, Bolund C, Gustafsson UL, Sjoden PO. (1994) A randomized study of a rehabilitation program for cancer patients: the 'starting again' group. Psycho-Oncology 3:109-120.
81. Berglund G, Bolund C, Gustafsson UL, Sjoden PO. (1994) One-year follow-up of the 'starting again' group rehabilitation programme for cancer patients. Eur J Cancer 30A:1744-1751.
82. Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G. (2005) Physical exercise in cancer patients during and after medical treatment: A systematic review of randomized and controlled clinical trials. J Clin Oncol 23:3830-3842.
83. Courneya KS, Segal RJ, Reid RD, Jones LW, Malone SC, Venner PM, Parliament MB, Scott CG, Quinney HA, Wells GA. (2004) Three independent factors predicted adherence in a randomized controlled trial of exercise training among prostate cancer survivors. J Clin Epidem 57:571-579.